Doctors have raised a warning against so-called “trip killers” that are used to end challenging psychedelic experiences on compounds such as LSD or psilocybin.
Psychedelics Today recently surveyed students and graduates of its 12-month intensive professional psychedelic certification programme, Vital, publishing its findings in The Emerging Psychedelic Workforce report.
Ketamine is an FDA-approved medical anesthetic and recently a prescription nasal spray version of ketamine called esketamine (Spravato) was approved for treatment-resistant depression.
A new company specialising in psychedelic medicine – mychedelica – is offering a comprehensive suite of services to support the advancement of this transformative field.
Biotech company Clearmind Medicine has announced receipt of a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq.
A new paper has explored the extended difficulties experienced by some people following psychedelic drug use and discusses psychedelic harm reduction.
UK charity Transform Drug Policy Foundation has published a new book ‘How to Regulate Psychedelics: A Practical Guide’ that sets out how psychedelics can be legalised...
The Psychedelic Access and Research European Alliance (PAREA) has launched a policy paper in line with a recent meeting on medical psychedelics in the European Parliament.
Global investment firm Psych Capital has announced the completion of its 100% acquisition of life science company Short Wave Pharma.
For the first time since Australia rescheduled MDMA and psilocybin, a shipment of the compounds has been made to the country to be used under the...
